# Quercetin + Dasatinib

**Category:** protocol
**Evidence Grade:** C
**Risk Profile:** medium

## Description
First senolytic combination shown to clear senescent cells in humans

## Mechanisms of Action
- Senolytic — clears senescent cells
- Anti-inflammatory

## Dosage
- **Standard:** D:100mg + Q:1000mg, 3 days/month
- **Range:** Various protocols
- **Notes:** Intermittent dosing only. Dasatinib requires prescription.

## Key Findings
- First senolytic combination shown to clear senescent cells in humans
- Improved physical function in IPF patients
- Hit-and-run approach — cells cleared but drugs not continuously needed

## Interactions


## Side Effects


## Contraindications


## Sources


## Suppliers


---
*Last updated: 2026-02-04T08:33:44.508Z*
